Overview

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company